Equity Analysis /
United States of America

US : Sage Therapeutics, Inc. - SAGE | 324 KINETIC Data Leave Us With More Questions Than Answers; Viability of ET Program Unclear

    Danielle Brill
    Daniil Gataulin
    Daniil Gataulin

    Ph.D., Sr. Res. Assoc.

    CGS-CIMB
    12 April 2021
    Published by